Board Institutes Inter Partes Review Of Horizon Drug Patent

(September 29, 2017, 9:53 AM EDT) -- ALEXANDRIA, Va. — The Patent Trial and Appeal Board on Sept. 28 agreed to review various claims of a patented method of using the drug glyceryl tri-(4-phenylbutryate) (HPN-100) to treat subjects with urea cycle disorders (Lupin Ltd. and Lupin Pharmaceuticals Inc. v. Horizon Therapeutics LLC, No. IPR2017-01160, PTAB)....

Attached Documents

Related Sections